- Home
- FUBO vs ATXS Comparison
FUBO vs ATXS Comparison
Compare FUBO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUBO
- ATXS
- Stock Information
- Founded
- FUBO 2009
- ATXS 2008
- Country
- FUBO United States
- ATXS United States
- Employees
- FUBO N/A
- ATXS N/A
- Industry
- FUBO Broadcasting
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- FUBO Industrials
- ATXS Health Care
- Exchange
- FUBO Nasdaq
- ATXS Nasdaq
- Market Cap
- FUBO 534.5M
- ATXS 584.1M
- IPO Year
- FUBO 2020
- ATXS 2015
- Fundamental
- Price
- FUBO $1.37
- ATXS $9.56
- Analyst Decision
- FUBO Buy
- ATXS Strong Buy
- Analyst Count
- FUBO 6
- ATXS 5
- Target Price
- FUBO $2.88
- ATXS $28.00
- AVG Volume (30 Days)
- FUBO 14.4M
- ATXS 380.9K
- Earning Date
- FUBO 11-01-2024
- ATXS 11-13-2024
- Dividend Yield
- FUBO N/A
- ATXS N/A
- EPS Growth
- FUBO N/A
- ATXS N/A
- EPS
- FUBO N/A
- ATXS N/A
- Revenue
- FUBO $1,589,700,000.00
- ATXS N/A
- Revenue This Year
- FUBO $21.18
- ATXS N/A
- Revenue Next Year
- FUBO $11.64
- ATXS N/A
- P/E Ratio
- FUBO N/A
- ATXS N/A
- Revenue Growth
- FUBO 24.45
- ATXS N/A
- 52 Week Low
- FUBO $1.10
- ATXS $6.20
- 52 Week High
- FUBO $3.43
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- FUBO 38.75
- ATXS 42.48
- Support Level
- FUBO $1.66
- ATXS $9.17
- Resistance Level
- FUBO $1.83
- ATXS $9.99
- Average True Range (ATR)
- FUBO 0.11
- ATXS 0.60
- MACD
- FUBO -0.04
- ATXS -0.02
- Stochastic Oscillator
- FUBO 17.12
- ATXS 21.20
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segment of the group is Streaming. It has a business presence in the United States and other international countries.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.